304 related articles for article (PubMed ID: 26933988)
41. Why is there still hepatitis C transmission in Australian prisons? A case report.
Harkness B; Levy M; Evans R; Wenke J
Harm Reduct J; 2017 Nov; 14(1):75. PubMed ID: 29178927
[TBL] [Abstract][Full Text] [Related]
42. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting.
Lloyd AR; Clegg J; Lange J; Stevenson A; Post JJ; Lloyd D; Rudge G; Boonwaat L; Forrest G; Douglas J; Monkley D
Clin Infect Dis; 2013 Apr; 56(8):1078-84. PubMed ID: 23362288
[TBL] [Abstract][Full Text] [Related]
43. An audit of hepatitis C service provision in a representative sample of prisons in England.
Humphreys C; Railton C; O'Moore É; Lombard M; Newton A
J Public Health (Oxf); 2015 Mar; 37(1):151-6. PubMed ID: 24700887
[TBL] [Abstract][Full Text] [Related]
44. Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison.
Byrne CJ; Malaguti A; Inglis SK; Dillon JF
BMJ Open; 2023 Apr; 13(4):e068604. PubMed ID: 37037621
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
46. Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders.
Ruiz AS; Fontaine G; Patey AM; Grimshaw JM; Presseau J; Cox J; Dussault C; Kronfli N
Int J Drug Policy; 2022 Nov; 109():103837. PubMed ID: 36030569
[TBL] [Abstract][Full Text] [Related]
47. Substitution treatment and HCV/HIV-infection in a sample of 31 German prisons for sentenced inmates.
Schulte B; Stöver H; Thane K; Schreiter C; Gansefort D; Reimer J
Int J Prison Health; 2009; 5(1):39-44. PubMed ID: 25758928
[TBL] [Abstract][Full Text] [Related]
48. Palliative and end-of-life care in prisons: a content analysis of the literature.
Maschi T; Marmo S; Han J
Int J Prison Health; 2014; 10(3):172-97. PubMed ID: 25764177
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia.
Gates JA; Post JJ; Kaldor JM; Pan Y; Haber PS; Lloyd AR; Dolan KA;
J Urban Health; 2004 Sep; 81(3):448-52. PubMed ID: 15273267
[TBL] [Abstract][Full Text] [Related]
50. Hepatitis C Virus Elimination Program among Prison Inmates, Israel.
Eisen L; Mor Z; Madar M; Rabinovitch R; Dadon Y; Sheffer R; Kaliner E; Goldstein L
Emerg Infect Dis; 2023 Nov; 29(11):2358-2361. PubMed ID: 37877627
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis C in European prisons: a call for an evidence-informed response.
Arain A; Robaeys G; Stöver H
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S17. PubMed ID: 25252822
[TBL] [Abstract][Full Text] [Related]
52. The furthest left behind: the urgent need to scale up harm reduction in prisons.
Sander G; Murphy F
Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
[TBL] [Abstract][Full Text] [Related]
53. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.
Crowley D; Van Hout MC; Lambert JS; Kelly E; Murphy C; Cullen W
Harm Reduct J; 2018 Dec; 15(1):62. PubMed ID: 30538000
[TBL] [Abstract][Full Text] [Related]
54. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health.
Morris MD; Brown B; Allen SA
Int J Prison Health; 2017 Sep; 13(3-4):192-199. PubMed ID: 28914118
[TBL] [Abstract][Full Text] [Related]
55. Testing for hepatitis C virus infection in UK prisons: What actually happens?
Jack K; Thomson BJ; Irving WL
J Viral Hepat; 2019 Jun; 26(6):644-654. PubMed ID: 30702194
[TBL] [Abstract][Full Text] [Related]
56. Health promotion and young prisoners: a European perspective.
MacDonald M; Rabiee F; Weilandt C
Int J Prison Health; 2013; 9(3):151-64. PubMed ID: 25764388
[TBL] [Abstract][Full Text] [Related]
57. Detection of drugs in Australian prisons: supply reduction strategies.
Dolan K; Rodas A
Int J Prison Health; 2014; 10(2):111-7. PubMed ID: 25764074
[TBL] [Abstract][Full Text] [Related]
58. The effect of hepatitis C virus infection on health-related quality of life in prisoners.
Thein HH; Butler T; Krahn M; Rawlinson W; Levy MH; Kaldor JM; Dore GJ
J Urban Health; 2006 Mar; 83(2):275-88. PubMed ID: 16736376
[TBL] [Abstract][Full Text] [Related]
59. [Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain].
Martín Sánchez V; Ferrer Castro V; Pallas Álvarez JR; Alonso Herrero LE; Andrés Honorato M; Coterillo González MJ; García Marcos LS; González Márquez J; Hernández Alonso I; LLanos Gallegos M; Mallada García E; Martínez Martínez ML; Morillo Pérez M; Pérez Martínez I; Valles Martínez J
Rev Esp Salud Publica; 1998; 72(1):43-51. PubMed ID: 9477715
[TBL] [Abstract][Full Text] [Related]
60. Access to harm reduction and HIV-related treatment services inside Indian prisons: experiences of formerly incarcerated injecting drug users.
Chakrapani V; Kamei R; Kipgen H; Kh JK
Int J Prison Health; 2013; 9(2):82-91. PubMed ID: 25758440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
